![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Regeneron Gets Priority Review for Investigational High Cholesterol Drug
Regeneron Gets Priority Review for Investigational High Cholesterol Drug
The FDA has granted Regeneron’s evinacumab a priority review as an adjunct to other lipid-lowering therapies for the treatment of a rare inherited form of high cholesterol, homozygous familial hypercholesterolemia.
The company supported its biologics license application with results from a phase 3 trial in which patients who received evinacumab along with lipid-lowering therapies reduced their low-density lipoprotein (LDL) cholesterol by 49 percent at 24 weeks.
The FDA is expected to make a decision on the drug’s approval by Feb. 11, 2021.
Upcoming Events
-
21Oct